Flumazenil sublingual - Coeruleus

Drug Profile

Flumazenil sublingual - Coeruleus

Alternative Names: CRLS-035

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coeruleus
  • Class Antidotes; Benzodiazepinones
  • Mechanism of Action GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Sleep disorders
  • No development reported Insomnia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Insomnia(In volunteers) in Israel (Sublingual, Spray)
  • 01 Jul 2010 Phase-I clinical trials in Insomnia (In volunteers) in Israel (Sublingual)
  • 01 May 2010 Phase-I/II clinical trials in Sleep disorders (In volunteers) in Israel (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top